Hypothesis

Individuals with higher baseline abundance of butyrate-producing genera (Faecalibacterium, Coprococcus) show greater improvement in depressive symptoms after SSRI treatment, and this effect is mediated by vagus-nerve signaling that increases colonic HDAC inhibition through elevated butyrate levels.

Mechanistic Rationale

Butyrate acts as a histone deacetylase (HDAC) inhibitor, promoting neuroplasticity and anti‑inflammatory gene expression in the brain via the vagus nerve2. Prior work links low butyrate-producers to depressive phenotypes1. We propose that butyrate-producer abundance sets a permissive metabolic state: sufficient luminal butyrate reaches the portal circulation, activates vagal afferents, and suppresses central HDAC activity, thereby amplifying SSRI-induced serotonergic signaling. Conversely, low baseline producers limit this amplification, yielding poorer drug response regardless of serotonergic baseline.

Testable Predictions

1. Baseline stool Faecalibacterium/Coprococcus relative abundance will positively correlate with change in HAM-D scores after 8 weeks of SSRI monotherapy.
2. Pharmacological vagotomy (or vagal blockade) in animal models will abolish the behavioral benefit of butyrate supplementation on SSRI response.
3. Administering a sodium butyrate enema to low-producer patients will raise fecal butyrate to producer-level concentrations and improve SSRI efficacy to match high-producer responders.
4. Metabolomic profiling will show increased colonic butyrate and decreased hippocampal HDAC activity only in high-producer responders.

Experimental Design

• Human cohort: Recruit 120 medication-free adults with moderate major depressive disorder. Obtain baseline stool shotgun metagenomics, quantify Faecalibacterium and Coprococcus. Randomize to SSRI (escitalopram) or placebo for 8 weeks. Primary outcome: HAM-D change. Secondary: serum butyrate, vagal tone (heart-rate variability), peripheral HDAC activity.
• Animal validation: Use germ-free mice colonized with either high-butyrate or low-butyrate consortia. Treat with SSRI (fluoxetine) ± vagotomy. Measure immobility in forced-swap test, colonic butyrate, hippocampal HDAC activity, and corticosterone.
• Intervention arm: In a subset of low-producer human participants, give daily sodium butyrate enemas for 2 weeks prior to SSRI start; compare outcomes to matched low-producer controls.

Potential Confounds and Controls

• Dietary fiber intake will be recorded and used as a covariate.
• Concurrent use of antibiotics or probiotics will be exclusion criteria.
• Baseline inflammation (CRP) will be measured to adjust for immune effects.
• Medication adherence will be tracked via pill counts and plasma drug levels.

If the correlations hold and vagal blockade abolishes the effect, the hypothesis is supported; failure to observe any of the predictions would falsify the claim that baseline butyrate-producer abundance drives SSRI response via vagal-mediated HDAC inhibition.